FrancophonIA/ELRC3.0 huggingface dataset:
English: Pharmacodynamic effects
Danish: FARMAKOLOGISKE EGENSKABER
English: - For more than 12 hours: patients should take the next dose at the regular scheduled time
Danish: - Mere end 12 timer efter planlagt administration: patienten børskal tage næste dosis som
English: What Clopidogrel dura looks like and contents of the pack The film-coated tablets are pink, round and slightly convex.
Danish: De filmovertrukne tabletter er lyserøde, runde og let hvælvede.
English: • If you cut or injure yourself, it may take longer than usual for bleeding to stop.
Danish: • kan det vare lidt længere end normalt, før blødningen ophører, hvis du skærer dig eller kommer til skade.
English: Bleeding time prolonged, neutrophil count decreased, platelet count decreased * Information related to clopidogrel with frequency “not known”.
Danish: * Information relateret til clopidogrel med hyppighed ”ikke kendt”.
English: You should check with your doctor or pharmacist if you are not sure.
Danish: Spørg lægen eller på apotekspersonalet, hvis der er noget, du er i tvivl om.
English: Clopidogrel has no or negligible influence on the ability to drive and use machines.
Danish: 4.7 Virkning på evnen til at føre motorkøretøj og betjene maskiner Clopidogrel påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene
English: • Adults patients suffering from myocardial infarction (from a few days until less than 35 days),
Danish: • Voksne patienter med myokardieinfarkt (fra få dage, men ikke over 35 dage), iskæmisk apopleksi (fra 7 dage, men ikke over 6 måneder) eller påviste perifere kredsløbsforstyrrelser.
English: Consequently, NSAIDs including Cox-2 inhibitors and clopidogrel should be co-administered with caution (see section 4.4).
Danish: Derfor bør samtidig administration af NSAID'er inklusive cox-2-hæmmere og clopidogrel
English: • Paediatric population
Danish: • Nedsat leverfunktion
English: Musculo-skeletal bleeding (haemarthrosis), arthritis, arthralgia, myalgia
Danish: Gastrointestinal blødning, diarré, mavesmerter, dyspepsi
English: By preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming (a process called thrombosis).
Danish: Ved at forhindre denne sammenklumpning nedsætteren blodpropopløsende medicin, risikoen for, at der dannes blodpropper
English: You should specifically tell your doctor if you take - oral anticoagulants, medicines used to reduce blood clotting, - a non-steroidal anti-inflammatory medicine, usually used to treat painful and/or inflammatory
Danish: Det er særlig vigtigt, at du fortæller det til din læge, hvis du tager: - blodfortyndende medicin, der tages gennem munden og avendes til at nedsætte dannelse af
English: Rare side effect (may affect up to 1 in 1000 people): Vertigo.
Danish: Sjældne bivirkninger (kan påvirke op til 1 ud af 1.000 patienter):
English: The most common side effect reported is bleeding.
Danish: De alvorligste bivirkninger er anført først.
English: The concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.5).
Danish: Samtidig administration af clopidogrel og orale antikoagulantia kan ikke anbefales, da det kan øge
English: Mylan SAS
Danish: Mavetarmkanalen
English: Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription.
Danish: Brug af anden medicin sammen med Clopidogrel dura Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for
English: Ask your doctor or pharmacist for advice before taking any medicine.
Danish: - Spørg lægen eller på apotekspersonalet, hvis der er mere, De vil vide.
English: - This medicine has been prescribed for you only.
Danish: - Lægen har ordineret Clopidogrel dura til dig personligt.
English: SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
Danish: EVENTUELLE SÆRLIGE FORHOLDSREGLER VED BORTSKAFFELSE AF IKKE
English: If you forget to take Clopidogrel dura:
Danish: Det skal du vide, før du begynder at tage Clopidogrel dura
English: Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the member states
Danish: Bilag I Fortegnelse over lægemidlernes navne, lægemiddelformer, styrker, indgivelsesveje, indehavere af markedsføringstilladelser i medlemsstaterne
English: Neo Psychiko 15451 Greece
Danish: Neo Psychiko 15451
English: S.C. Magistra C&C Str. Aurel Vlaicu nr. 82A 8700 Constanţa România
Danish: Rumænien S.C. Magistra C&C Str. Aurel Vlaicu nr. 82A 8700 Constanţa
English: United Kingdom Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe
Danish: Storbritannien Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe
English: 821 08 Bratislava
Danish: 821 08 Bratislava Slovak Republic
English: Rafarm AEBE Korinthou 12
Danish: Grækenland Rafarm AEBE Korinthou 12
English: Str. Ştefan Mihăileanu nr. 31 Sector 2, Bucureşti
Danish: Arena Group S.A. Str. Ştefan Mihăileanu nr. 31 Sector 2, Bucureşti
English: Coup ABEE Agias Barbaras 53-55 Dafni 15235
Danish: Grækenland Coup ABEE Agias Barbaras 53-55 Dafni 15235
English: 21ST Km National Highway Athens - Lamia Kryoneri 14568
Danish: Grækenland Demo ABEE 21ST Km National Highway Athens - Lamia Kryoneri 14568
English: Slovak Republic Johnson & Johnson s.r.o.
Danish: Johnson & Johnson s.r.o.
English: Karla Engliše 3201/6
Danish: Karla Engliše 3201/6 15000 Praha 5
English: S.C. Slavia Pharm S.R.L.
Danish: Rumænien S.C. Slavia Pharm S.R.L.
English: Terapia SA Str. Fabricii nr. 124 Cluj-Napoca Romania
Danish: Rumænien Terapia SA Str. Fabricii nr. 124
English: 1-10 Constantinoupoleos street 3505 Lemesos
Danish: Medochemie ltd 1-10 Constantinoupoleos street 3505 Lemesos
English: A.C. Helcor s.r.l.
Danish: Helcor s.r.l.
English: Angelini Pharma Hellas ABEE Achaias & Trizinias Nea Kifissia 14564
Danish: Grækenland Angelini Pharma Hellas ABEE Achaias & Trizinias
English: Belgium Janssen-Cilag NV Antwerpseweg 15-17
Danish: Janssen-Cilag NV Antwerpseweg 15-17 2340 Beerse Belgium
English: 5026 RH TILBURG
Danish: Dr. Paul Janssenweg 150 5026 RH TILBURG The Netherlands
English: S.C.
Danish: Rumænien S.C.
English: Demo ABEE
Danish: Cluj-Napoca
English: Bros ltd
Danish: Grækenland Bros ltd Avgis & Galinis 15
English: Recovery* > 21 days
Danish: Restituering* > 21 dage
English: Also contains mannitol.
Danish: Indeholder også mannitol.
English: They are also responsible for preparing and disposing of any unused Azacitidine Celgene correctly.
Danish: De er også ansvarlige for at forberede og bortskaffe al ubrugt Azacitidin Celgene på korrekt vis.
English: Dose mg/m (% of recommended starting dose)
Danish: Dosis mg/m (% af anbefalet startdosis)
English: • Azacitidine Celgene is given every day for one week, followed by a rest period of 3 weeks.
Danish: • Azacitidin Celgene gives hver dag i en uge, efterfulgt af en hvileperiode på 3 uger.
English: The following table is provided only as an example of how to calculate individual azacitidine doses based on an average BSA value of 1.8 m
Danish: Følgende tabel er kun et eksempel på, hvordan individuelle azacitidindoser beregnes baseret på en gennemsnitlig BSA-værdi på 1,8 m
English: Health- Related Quality of Life (HRQoL) was assessed using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30).
Danish: Sundhedsrelateret livskvalitet (Health- Related Quality of Life, HRQoL) blev vurderet ved hjælp af European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30).
English: The individual baseline parameters were comparable between the azacitidine and CCR groups.
Danish: De individuelle baseline-parametre var sammenlignelige mellem grupperne med azacitidin og CCR.
English: Unopened powder vial: 4 years
Danish: Uåbnet hætteglas med pulver: 4 år
English: Total dose (mg) = Dose (mg/m 2) x BSA (m
Danish: Samlet dosis (mg) = Dosis (mg/m 2) x BSA(m
English: While there are limitations in the analysis, the available data suggest that patients do not experience meaningful deterioration in quality of life during treatment with azacitidine.
Danish: Selvom der er begrænsninger i analysen, tyder de tilgængelige data på, at patienterne ikke oplever betydelige forringelser i livskvalitet under behandling med azacitidin.
English: • intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
Danish: • intermediær-2 og højrisiko myelodysplastiske syndromer (MDS) i henhold til International Prognostic Scoring System (IPSS),
English: You should not use Azacitidine Celgene during pregnancy as it may be harmful to the baby.
Danish: Du bør ikke bruge Azacitidin Celgene under graviditet, da det kan være skadeligt for fosteret.
English: Total dose based on BSA value of 1.8 m
Danish: Samlet dosis baseret på en BSA-værdi på 1,8 m
English: Investigations weight decreased * = rarely fatal cases have been reported
Danish: Undersøgelser vægttab *= der er i sjældne tilfælde rapporteret letale tilfælde
English: This is because Azacitidine Celgene may affect the way some other medicines work.
Danish: Det skyldes, at Azacitidin Celgene kan påvirke den måde, hvorpå anden medicin virker.
English: Children and adolescents Azacitidine Celgene is not recommended for use in children and adolescents below the age of 18.
Danish: Børn og unge Azacitidin Celgene bør ikke anvendes til børn og unge under 18 år.
English: KEY: AZA = azacitidine; CCR = conventional care regimens; CI = confidence interval; HR = hazard ratio
Danish: FORKORTELSER: AZA = azacitidin; CCR = konventionelle behandlingsregimer (conventional care regimens); CI = konfidensinterval; HR = hazard ratio
English: Azacitidine Celgene treatment should be initiated and monitored under the supervision of a physician experienced in the use of chemotherapeutic agents.
Danish: Behandling med Azacitidin Celgene bør initieres og monitoreres under supervision af en læge, der har erfaring i anvendelsen af kemoterapeutika.
English: Azacitidine plus BSC (n=241) was compared to CCR.
Danish: Azacitidin plus BSC (n=241) blev sammenlignet med CCR.
English: Azacitidine treatment was also associated with a reduction in cytopenias, and their related symptoms.
Danish: Behandling med azacitidin var ligeledes associeret med en reduktion i cytopenier og deres relaterede symptomer.
English: The Azacitidine Celgene suspension may be prepared immediately before use and the reconstituted suspension should be administered within 45 minutes.
Danish: Suspensionen med Azacitidin Celgene kan klargøres umiddelbart før brug, og den rekonstituerede suspension skal administreres inden for 45 minutter.
English: The safety and efficacy of Azacitidine Celgene in children aged 0-17 years have not yet been established.
Danish: Azacitidin Celgenes sikkerhed og virkning hos børn i alderen 0-17 år er endnu ikke klarlagt.
English: Before giving you Azacitidine Celgene, your doctor will give you another medicine to prevent nausea and vomiting at the start of each treatment cycle.
Danish: Inden du får Azacitidin Celgene vil din læge give dig anden medicin for at forebygge kvalme og opkastning ved begyndelsen af hver behandlingscyklus.
English: Your doctor, pharmacist or nurse are responsible for storing Azacitidine Celgene.
Danish: Din læge, apoteket eller sundhedspersonalet er ansvarlig for opbevaringen af Azacitidin Celgene.
English: • The recommended dose is 75 mg per m body surface area.
Danish: • Den anbefalede dosis er 75 mg pr. m legemsoverfladeareal.
English: • Infection of the deeper layers of skin, which spreads quickly, damaging the skin and tissue, which can be life-threatening (necrotizing fasciitis).
Danish: • Infektion i de dybere hudlag, som spredes hurtigt og beskadiger huden og vævet, hvilket kan være livstruende (nekrotiserende fasciitis).
English: D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Danish: D. BETINGELSER ELLER BEGRÆNSINGER MED HENSYN TIL SIKKER OG EFFEKTIV ANVENDELSE AF LÆGEMIDLET
English: A patient experienced diarrhoea, nausea, and vomiting after receiving a single intravenous dose of approximately 290 mg/m almost 4 times the recommended starting dose.
Danish: En patient fik diarré, kvalme og opkastning efter at have fået en enkelt intravenøs dosis af ca. 290 mg/m2, hvilket er næsten 4 gange den anbefalede startdosis.
English: Once the suspension has been prepared it should be administered within 45 minutes.
Danish: Til umiddelbar anvendelse Når suspensionen er blevet forberedt, bør den administreres i løbet af 45 minutter.
English: Azacitidine Celgene should be reconstituted with water for injections.
Danish: Azacitidin Celgene skal rekonstitueres med vand til injektionsvæsker.
English: Azacitidine Celgene is a cytotoxic medicinal product and, as with other potentially toxic compounds, caution should be exercised when handling and preparing azacitidine suspensions.
Danish: Azacitidin Celgene er et cytotoksisk lægemiddel, og som det er tilfældet med andre potentielt toksiske stoffer, bør der udvises forsigtighed ved håndtering og klargøring af azacitidinsuspensioner.
English: Azacitidine Celgene works by preventing cancer cells from growing.
Danish: Azacitidin Celgene virker ved at forhindre kræftcellernes vækst.
English: You will have blood tests before you begin treatment with Azacitidine Celgene and at the start of each period of treatment (called a ‘cycle').
Danish: Du vil få taget blodprøver, inden du påbegynder behandlingen med Azacitidin Celgene og ved begyndelsen af hver behandlingsperiode (kaldet en ”cyklus”).
English: Following intravenous and subcutaneous administration of C-azacitidine, 85 and 50 % of the administered radioactivity was recovered in urine respectively, while < 1 % was recovered in faeces.
Danish: Efter intravenøs og subkutan administration af C-azacitidin, blev hhv. 85 og 50 % af den administrerede radioaktivitet genfundet i urin, mens < 1 % blev genfundet i fæces.
English: 9/L), baseline bone marrow blasts (≤ 50% & > 50%) and prior history of MDS] there was a trend in OS benefit in favour of azacitidine.
Danish: 9/l), knoglemarvsblaster ved baseline (≤ 50 % og > 50 %) samt tidligere MDS] var der en tendens til en OS-fordel for azacitidin.
English: Talk to your doctor or nurse if you have any questions about how Azacitidine Celgene works or why this medicine has been prescribed for you.
Danish: Kontakt lægen eller sundhedspersonalet, hvis du har spørgsmål om Azacitidin Celgenes virkning, og hvorfor du har fået ordineret dette lægemiddel.
English: Azacitidine Celgene contains the active substance ‘azacitidine'.
Danish: Azacitidin Celgene indeholder det aktive stof 'azacitidin '.
English: Patients without reduced baseline blood counts (i.e. White Blood Cells (WBC) ≥ 3.0 x 10
Danish: Patienter uden reducerede hæmatologiske parametre ved baseline (dvs. hvide blodlegemer (White Blood Cells, WBC) ≥ 3,0 x 10
English: Azacitidine Celgene is an anti-cancer agent which belongs to a group of medicines called ‘antimetabolites'.
Danish: Azacitidin Celgene er et stof mod kræft, der tilhører en gruppe lægemidler, der kaldes 'antimetabolitter '.
English: The absolute bioavailability of azacitidine after subcutaneous relative to intravenous administration (single 75 mg/m doses) was approximately 89% based on area under the curve (AUC).
Danish: Den absolutte biotilgængelighed af azacitidin efter subkutan administration i forhold til intravenøs administration (enkeltdoser på 75 mg/m2) var ca. 89 % baseret på arealet under kurven (AUC).
English: Adult population with MDS, CMML and AML (20-30% marrow blasts) Adverse reactions considered to be possibly or probably related to the administration of azacitidine have occurred in 97 % of patients.
Danish: Voksenpopulation med MDS, CMML og AML (20-30 % knoglemarvsblaster) Bivirkninger, der muligvis eller sandsynligvis kan relateres til administrationen af azacitidin, forekom hos 97 % af patienterne.
English: No accumulation occurs after subcutaneous administration of 75 mg/m azacitidine once daily for 7 days.
Danish: Der forekommer ingen akkumulering efter subkutan indgivelse af 75 mg/m azacitidin én gang dagligt i 7 dage.
English: Azacitidine Celgene therapy should be discontinued in patients who develop necrotising fasciitis and appropriate treatment should be promptly initiated.
Danish: Behandling med Azacitidin Celgene bør seponeres hos patienter, der udvikler nekrotiserende fasciitis, og der skal omgående påbegyndes passende behandling.
English: The Cox PH model adjusted for pre-specified baseline prognostic factors defined a HR for azacitidine versus CCR of 0.80 (95% CI= 0.66, 0.99; p = 0.0355).
Danish: Cox-PH-modellen justeret for præspecificerede prognostiske faktorer ved baseline definerede en HR for azacitidin versus CCR på 0,80 (95% CI= 0,66; 0,99; p = 0,0355).
English: Powder for suspension for injection.
Danish: Pulver til injektionsvæske, suspension.
English: A survival benefit was also demonstrated in patients that had not achieved a complete response for azacitidine compared to CCR.
Danish: Der blev også vist overlevelsesfordel hos patienter, der ikke havde opnået et fuldstændigt respons, for azacitidin, sammenlignet med CCR.
English: 9/l) prior to the first treatment
Danish: 9/l) inden første behandling
English: Men should not father a child while receiving treatment with Azacitidine Celgene.
Danish: Mænd bør ikke få børn, mens de behandles med Azacitidin Celgene.
English: Also, some other medicines may affect the way Azacitidine Celgene works.
Danish: Anden medicin kan også påvirke den måde, hvorpå Azacitidin Celgene virker.
English: Unopened vials This medicinal product does not require any special storage conditions.
Danish: Uåbnede hætteglas Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen.
English: Haematological toxicity is defined as the lowest count reached in a given cycle (nadir) if platelets ≤ 50.0 x 10
Danish: Hæmatologisk toksicitet defineres som den laveste hæmatologiske parameter i en given cyklus (nadirtal), såfremt trombocytterne ≤ 50,0 x 10
English: The one-year survival rates were 46.5% in patients receiving azacitidine versus 34.3% in patients receiving CCR.
Danish: Overlevelsesrate efter et år var 46,5 % hos patienter i behandling med azacitidin versus 34,3 % hos patienter, der fik CCR.
English: The efficacy and safety of azacitidine was studied in an international, multicentre, controlled, openlabel, parallel group Phase 3 study in patients 65 years and older with newly diagnosed de novo or secondary AML with >30% bone marrow blasts according to the WHO classification, who were not eligible for HSCT.
Danish: Azacitidins virkning og sikkerhed blev undersøgt i et internationalt, kontrolleret, åbent fase IIImulticenterstudie med parallelle grupper hos patienter i alderen 65 år og derover med nydiagnosticeret de novo eller sekundær AML med > 30 % knoglemarvsblaster i henhold til WHO-klassifikationen, som ikke var egnede til HSCT.
English: Read the leaflet for the shelf life of the reconstituted medicine.
Danish: Læs indlægssedlen for opbevaringstiden for det rekonstituerede lægemiddel.
English: • acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,
Danish: • akut myeloid leukæmi (AML) med 20-30 % blaster og multilinjedysplasi i henhold til klassifikationen fra World Health Organisation (WHO).
English: Reconstituted Azacitidine Celgene should be injected subcutaneously (insert the needle at a 45-90° angle) using a 25-gauge needle into the upper arm, thigh or abdomen.
Danish: Rekonstitueret Azacitidin Celgene bør injiceres subkutant (indfør kanylen ved en vinkel på 45-90°) med en 25 gauge-kanyle i overarmen, låret eller maven.
English: 1 vial - 100 mg
Danish: 1 hætteglas - 100 mg
English: Patients received this pre-selected regimen if not randomised to azacitidine.
Danish: Patienterne fik dette prædefinerede regime, hvis de ikke blev randomiseret til azacitidin.
English: 2 D bar code carrying the unique identifier
Danish: Der er anført en 2D-stregkode, som indeholder en entydig identifikator.
English: Adult population (MDS, CMML and AML [20-30% marrow blasts]) The efficacy and safety of azacitidine were studied in an international, multicenter, controlled, openlabel, randomised, parallel-group, Phase 3 comparative study (AZA PH GL 2003 CL 001) in adult patients with: intermediate-2 and high-risk MDS according to the International Prognostic Scoring System (IPSS), refractory anaemia with excess blasts (RAEB), refractory anaemia with excess blasts in transformation (RAEB-T) and modified chronic myelomonocytic leukaemia (mCMML) according to the French American British (FAB) classification system.
Danish: Voksenpopulation (MDS, CMML og AML [20-30 % knoglemarvsblaster]) azacitidins virkning og sikkerhed blev undersøgt i et international, kontrolleret, open-label, randomiseret, komparativ, parallel-gruppe, fase 3-multicenterstudie (AZA PH GL 2003 CL 001) hos voksne patienter med: intermediær-2 og højrisiko MDS i henhold til International Prognostic Scoring System (IPSS), refraktær anæmi med overskud af blaster (RAEB), refraktær anæmi med overskud af blaster i transformation (RAEB-T) og modificeret kronisk myelomonocytleukæmi (mCMML) i henhold til French American British-(FAB-) klassifikationen.
English: Absorption Following subcutaneous administration of a single 75 mg/m dose, azacitidine was rapidly absorbed with peak plasma concentrations of 750 ± 403 ng/mL occurring at 0.5 h after dosing (the first sampling point).
Danish: Absorption Efter subkutan administration af en enkelt dosis på 75 mg/m blev azacitidin hurtigt absorberet med peak-plasma-koncentrationer på 750 ± 403 ng/ml ½ time efter dosering (det første prøvetagningstidspunkt).
English: In addition, although the study was not powered to demonstrate a statistically significant difference when comparing azacitidine to the preselection CCR treatment groups, the survival of azacitidine treated patients was longer when compared to CCR treatment options BSC alone, low-dose cytarabine plus BSC and were similar when compared to standard intensive chemotherapy plus BSC.
Danish: Selvom studiet ikke havde styrke til at vise en statistisk signifikant forskel ved sammenligning af azacitidin med præselektions-CCR-behandlingsgrupperne, var overlevelsesfordelen ved azacitidin desuden længere ved sammenligning med CCR-behandlingsmulighederne BSC alene, lavdosiscytarabin plus BSC, og den var sammenlignelig med standard intensiv kemoterapi plus BSC.
English: Azacitidine was administered at a subcutaneous dose of 75 mg/m daily for 7 days, followed by a rest period of 21 days (28-day treatment cycle) for a median of 9 cycles (range = 1-39) and a mean of 10.2 cycles.
Danish: Azacitidin blev administreret ved en subkutan dosis på 75 mg/m dagligt i 7 dage, efterfulgt af en hvileperiode på 21 dage (28 dages behandlingscyklus) i en median på 9 cyklusser (range = 1-39) og et gennemsnit på 10,2 cyklusser.
English: Azacitidine Celgene is used in adults who are not able to have a stem cell transplantation to treat:
Danish: Azacitidin Celgene anvendes til voksne, som ikke er i stand til at få en knoglemarvstransplantation, til at behandle:
English: Azacitidine treatment was associated with a median time to death or transformation to AML of 13.0 months versus 7.6 months for those receiving CCR treatment, an improvement of 5.4 months with a stratified log-rank p-value of 0.0025.
Danish: Behandling med azacitidin var associeret med en median tid til dødsfald eller transformation til AML på 13,0 måneder kontra 7,6 måneder for de patienter, der fik CCR-behandling, hvilket er en forbedring på 5,4 måneder med en stratificeret log-rank p-værdi på 0,0025.